Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y375
UPID:
CIA30_HUMAN
Alternative names:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 1
Alternative UPACC:
Q9Y375; Q9BVZ5
Background:
Complex I intermediate-associated protein 30, mitochondrial, also known as NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 1, plays a crucial role in the assembly of the mitochondrial complex I. This protein is pivotal for the proper function of mitochondria, the powerhouses of the cell.
Therapeutic significance:
Linked to Mitochondrial complex I deficiency, nuclear type 11, a condition with a spectrum of disorders including neurodegenerative diseases and cardiomyopathy. Understanding the role of Complex I intermediate-associated protein 30 could open doors to potential therapeutic strategies.